Tarceva Battles Lung Cancer in Some (HealthDay)

Your Health Matters

HealthDay – THURSDAY, July 21 (HealthDay News) — New research finds that the
targeted cancer drug Tarceva nearly triples the amount of time lung cancer
patients survive without a recurrence and has fewer side effects than
standard chemotherapy.

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave